Chimeric Therapeutics Limited
CHMMF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $3,969 | $0 | $4,506 | $2,617 |
| % Growth | – | -100% | 72.2% | – |
| Cost of Goods Sold | $847 | $4 | $0 | $950 |
| Gross Profit | $3,122 | -$4 | $4,506 | $1,667 |
| % Margin | 78.7% | – | 100% | 63.7% |
| R&D Expenses | $9,762 | $11,148 | $14,432 | $6,116 |
| G&A Expenses | $7,052 | $8,998 | $11,924 | $9,138 |
| SG&A Expenses | $7,052 | $9,567 | $11,924 | $11,074 |
| Sales & Mktg Exp. | $0 | $573 | $0 | $3,183 |
| Other Operating Expenses | $1,419 | $0 | $3,130 | $0 |
| Operating Expenses | $18,233 | $20,715 | $29,487 | $17,190 |
| Operating Income | -$15,111 | -$20,719 | -$25,078 | -$15,092 |
| % Margin | -380.8% | – | -556.6% | -576.7% |
| Other Income/Exp. Net | $4,792 | -$515 | -$330 | -$627 |
| Pre-Tax Income | -$10,320 | -$21,234 | -$25,408 | -$15,735 |
| Tax Expense | $111 | -$8,704 | $93 | $164 |
| Net Income | -$10,430 | -$12,530 | -$25,500 | -$15,898 |
| % Margin | -262.8% | – | -566% | -607.5% |
| EPS | -0.008 | -0.018 | -0.059 | -0.044 |
| % Growth | 57.2% | 69.4% | -33.3% | – |
| EPS Diluted | -0.008 | -0.018 | -0.059 | -0.044 |
| Weighted Avg Shares Out | 1,351,924 | 695,640 | 433,245 | 359,932 |
| Weighted Avg Shares Out Dil | 1,351,924 | 695,640 | 433,245 | 359,932 |
| Supplemental Information | – | – | – | – |
| Interest Income | $48 | $121 | $28 | $13 |
| Interest Expense | $211 | $332 | $774 | $640 |
| Depreciation & Amortization | $1,032 | $1,082 | $965 | $950 |
| EBITDA | -$9,077 | -$11,224 | -$24,016 | -$13,623 |
| % Margin | -228.7% | – | -533% | -520.5% |